Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Abdulla A. Damluji: Cardiovascular Outcomes with Tirzepatide Versus Dulaglutide in Type 2 Diabetes
Dec 22, 2025, 12:39

Abdulla A. Damluji: Cardiovascular Outcomes with Tirzepatide Versus Dulaglutide in Type 2 Diabetes

Abdulla A. Damluji, Director of the Cardiovascular Center on Aging at Cleveland Clinic, has shared a post on X:

“Check out my latest article: Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease via LinkedIn”

Title: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

Authors: Stephen J. Nicholls, Imre Pavo, Deepak L. Bhatt, John B. Buse, Stefano Del Prato, Steven E. Kahn, A. Michael Lincoff, Darren K. McGuire, Debra Miller, Michael A. Nauck, Hiroshi Nishiyama, Steven E. Nissen, Naveed Sattar, Govinda Weerakkody, Russell J. Wiese, Bernard Zinman, Sophia Zoungas, Jan Basile, Melanie J. Davies, Francesco Giorgino, Monika Kellerer, Linong Ji, Tamas Varkonyi, Venu Menon, Jonathan C. Broder, Alan Herschtal, David D’Alessio, Eli Lilly and Company, SURPASS-CVOT Investigators

Abdulla A. Damluji: Cardiovascular Outcomes with Tirzepatide Versus Dulaglutide in Type 2 Diabetes

Discover the latest in Hemostasis Today.